文献速递生殖医学

游泳法与密度梯度法在宫腔内人工授精不育夫妇精子制备中的随机临床试验

Swim-up versus density gradients for sperm preparation in infertile couples undergoing intrauterine insemination: a randomized clinical trial.
PubMed 文献 · Hum Reprod · 2025-01-01

这项在越南两个试管婴儿中心进行的开放标签随机临床试验,将912对不育夫妇随机分为游泳法(SU)组456对和密度梯度法(DG)组456对,比较两种精子制备方法在宫腔内人工授精(IUI)中的效果。首次IUI周期后活产率SU组为12.1%(55对),DG组为15.7%(71对),相对风险0.77(95%CI 0.56至1.07),两组无统计学显著差异。

要点

  • SU组与DG组首次IUI周期后活产率分别为12.1%和15.7%,差异无统计学意义(RR 0.77,95%CI 0.56至1.07)。
  • 两组在其他妊娠结局及产科和围产结局方面均无统计学显著差异。
  • 作者认为SU和DG均可用于IUI精子制备,选择可能更多取决于处理时间和标准化难易等实际因素。

核心结论

  • 在不育夫妇IUI中,SU和DG两种精子制备方法的活产率无统计学显著差异。
  • 作者认为SU和DG均可用于IUI精子制备,选择可能更多取决于处理时间和标准化难易等实际因素。

研究设计与样本

  • 开放标签、两中心随机临床试验,在越南两个试管婴儿中心进行。
  • 样本量估算需912对夫妇以检测SU与DG之间5%的差异(把握度0.80,双侧α 5%,失访和交叉率10%)。
  • 随机化采用计算机生成的随机列表,可变区组大小为2、4或6,通过门户网站分配。
  • 纳入标准:夫妇年龄≥18岁,丈夫精子制备前精子浓度≥5×10^6/ml、前向运动率≥32%、前向运动精子总数>5×10^6(根据WHO 2010标准)。
  • 排除使用冷冻精液或丈夫精液高黏稠的夫妇。

主要发现

  • 2020年8月7日至2022年10月29日期间,共随机分配456对夫妇至SU组和456对至DG组。
  • 首次IUI周期后活产:SU组55对(12.1%),DG组71对(15.7%),相对风险0.77(95%CI 0.56至1.07)。
  • 两组在其他妊娠结局以及产科和围产结局方面均无统计学显著差异。

临床怎么用

  • 作者认为在不育夫妇IUI中,SU和DG均可用于精子制备。
  • 作者认为选择哪种方法可能更多取决于处理时间和标准化难易等实际因素。

局限性

  • 主要局限性为开放标签设计,源于干预措施的性质。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What is the effectiveness of swim-up (SU) and density gradients (DG) for sperm preparation in infertile couples undergoing IUI? SUMMARY ANSWER: In infertile couples undergoing IUI, SU and DG did not result in statistically significant different live birth rates. WHAT IS KNOWN ALREADY: SU and DG are the two most commonly used techniques for sperm preparation in infertile couples undergoing IUI. In the latest Cochrane review, given the very low quality of available data, the authors were uncertain whether there was a difference in clinical pregnancy rates between the two techniques. Furthermore, live birth rate was not reported in any trial. STUDY DESIGN, SIZE, DURATION: This open-label, two-centre, randomized clinical trial was conducted at two IVF centres in Vietnam. A sample size of 912 couples was needed to demonstrate a 5% difference between SU and DG (power 0.80, two-sided alpha 5%, loss to follow-up, and cross-over rate 10%). Randomization was performed using a computer-generated random list, with a variable block size of 2, 4, or 6. Assignment to treatment allocation was done via a web portal. PARTICIPANTS/MATERIALS, SETTING, METHODS: Eligible couples included those who were ≥18 years of age, where the husbands' sperm concentration, progressive motility (PM) rate, and total PM sperm count before sperm preparation were ≥5 × 106/ml, ≥32%, and >5 × 106 (according to the WHO 2010 criteria), respectively. Couples using frozen semen, or couples where the husband's semen was hyperviscous, were not included. On the day of IUI, participants were randomized (1:1 ratio) to undergo either SU or DG. Sperm preparation was performed within 1 h after ejaculation. IUI was performed once at 36-40 h after hCG trigger. Primary outcome was live birth after the first IUI cycle. MAIN RESULTS AND THE ROLE OF CHANCE: Between 7 August 2020 and 29 October 2022, we randomized 456 couples to SU and 456 couples to DG. Live birth after the first IUI cycle occurred in 55 (12.1%) couples in the SU group and 71 (15.7%) couples in the DG group (relative risk 0.77; 95% CI 0.56 to 1.07). There were no statistically significant differences between the two groups in terms of other pregnancy outcomes as well as obstetrics and perinatal outcomes. LIMITATIONS, REASONS FOR CAUTION: The main limitation of the study was its open-label design, due to the nature of the interventions. WIDER IMPLICATIONS OF THE FINDINGS: In infertile couples undergoing IUI, SU and DG can both be used for sperm preparation. The decision on which to use might depend more on practical factors such as processing time and how easy it is to standardize the method. STUDY FUNDING/COMPETING INTEREST(S): The study was funded by My Duc Hospital, Ho Chi Minh City, Vietnam. B.W.M. is supported by a NHMRC Investigator grant (GNT1176437), reports consultancy, travel support, and research funding from Merck and consultancy for Organon and Norgine, and holds stock from ObsEva. L.N.V. has received grant, speaker, and conference fees from Merck Sharpe and Dohme, and grant, speaker, conference, and scientific board fees from Ferring. T.M.H. has received grant, speaker, and conference fees from Merck Sharpe and Dohme, and grant, speaker, conference, and scientific board fees from Ferring. TRIAL REGISTRATION NUMBER: NCT04477356. TRIAL REGISTRATION DATE: 6 July 2020. DATE OF FIRST PATIENT’S ENROLMENT: 10 August 2020.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Duong TND, Dang VQ, Le TK, et al. Swim-up versus density gradients for sperm preparation in infertile couples undergoing intrauterine insemination: a randomized clinical trial. Hum Reprod. 2025. PMID: 40135621. doi:10.1093/humrep/deaf047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。